A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers

作者：Han, Yang; Lu, Su; Yu, Fudong; Liu, Xisheng; Sun, Huimin; Wang, Jingtao; Zhu, Xingwu; Lu, Huijun; Yue, Hao; Wang, Jing; Lin, Jun; Zhou, C*******; Tang, Huamei^*; Peng, Zhihai^*

来源：Scientific Reports, 2016, 6(1): 37240.

DOI：10.1038/srep37240

• COLON-CANCER
• ADJUVANT CHEMOTHERAPY
• BREAST-CANCER
• INDEPENDENT VALIDATION
• MOLECULAR PATHOLOGY
• GENE-EXPRESSION
• POOLED ANALYSIS
• OLDER PATIENTS
• FLUOROURACIL
• OXALIPLATIN

Adjuvant chemotherapy is considered the standard of care for patients with colorectal cancer after curative resection. Although current guidelines provide clear instructions for chemotherapy for stage II high-risk and stage III colorectal cancer, it is insufficient to individualize therapy. We analyzed the outcomes of 902 patients with colorectal cancer treated with or without chemotherapy in our hospital. We found Chinese survival benefit for chemotherapy was consistent with current guidelines. Moreover, our data added to the evidence that chemotherapy might be used for elderly patients with stage II high-risk colorectal cancer. Pathological markers could predict response to individualize therapy in a convenient, fast and inexpensive way. We compared survivals of patients with stage II high-risk and stage III colorectal cancer with chemotherapy in different pathological markers expression, and furthermore used 458 colon adenocarcinoma samples from The Cancer Genome Atlas to verify our preliminary results. We confirmed TOPII alpha, EGFR and P170 may be sufficiently predictive markers to individualize chemotherapy. FOLFOX was the optimal adjuvant chemotherapy for patients with stage II high-risk and stage III colorectal cancer when TOPII alpha was positive or EGFR or P170 was negative.

• 出版日期2016-11-15
• 单位上海交通大学